Sprycel市場，按應用程式、年齡層、分銷管道、按地區

預計 2025 年Sprycel市場規模為 23.4 億美元，到 2032 年將達到 28.4 億美元，2025 年至 2032 年的年複合成長率為 2.8%。

Sprycel是Dasatinib的商品名，達沙替尼是一種用於治療某些類型癌症的藥物。它屬於蛋白酪氨酸激酶抑制劑 (TKI) 類藥物。Dasatinib透過抑制某些蛋白酪氨酸激酶的活性來發揮作用，酪胺酸Sprycel是參與癌細胞生長和擴散的酵素。 Sprycel 是一種標靶標靶藥物，主要用於治療某些類型的白血病，尤其是以費城染色體 (Ph+ALL) 和慢性骨髓性白血病(ALL)。 Sprycel的常見副作用包括疲勞、頭痛、噁心、腹瀉和液體儲存。有些患者可能會出現更嚴重的副作用，例如血球數低、肝損傷和出血。醫療保健提供者的密切監測對於管理和解決副作用非常重要。該藥物適用於被診斷為 CML 的成人和 12 個月或以上的兒童。此藥物也適用於同年齡層患有特定亞型急性淋巴性白血病（即費城染色體陽性，Ph+ALL）的成人和兒童。白血病是一種惡性腫瘤，涉及骨髓中發育的未成熟白血球。正常情況下，這些白血球成熟後進入血液，抵抗感染疾病並維持人體免疫系統。

市場動態：

預測期內，預計推動全球Sprycel市場成長的關鍵因素包括：目標適應症數量的增加、其療效和安全性、適應症的不斷擴展以及創新技術的進步。癌症研究和治療的進步，包括Sprycel等標靶治療的開發，擴大了醫護人員和患者的治療選擇。這導致Sprycel被擴大納入治療方法。

然而，激烈的競爭、專利到期、監管挑戰、副作用、定價和報銷預計將在預測期內阻礙全球Sprycel市場的成長。

本研究的主要特點

• 本報告對全球Sprycel市場進行了詳細分析，並以 2024 年為基準年，展示了預測期 2025-2032 的市場規模和年複合成長率（CAGR）。
• 它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
• 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的主要考察。
• 該報告涵蓋了全球Sprycel市場的主要企業概況，基於以下參數，例如公司亮點、產品系列、主要亮點、績效和策略。
• 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興車型、市場擴張和行銷策略做出明智的決策。
• 全球Sprycel市場報告迎合了該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
• 相關人員將透過用於分析全球Sprycel市場的各種策略矩陣更輕鬆地做出決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章市場動態、法規與趨勢分析

• 市場動態
  • 目標適應症的流行程度、療效和安全性以及適應症的擴展
  • 激烈的競爭、專利到期和監管挑戰
  • 創新進步
• 影響分析
• 主要亮點
• 監管情景
• 產品發布/核准
• PEST分析
• 波特分析
• 併購場景

4. 全球Sprycel市場 - 冠狀病毒 (COVID-19) 大流行的影響

• COVID-19流行病學
• 供需側分析
• 經濟影響

5. 全球Sprycel市場（按應用分類），2020 年至 2032 年

• 慢性骨髓性白血病（CML）
• 費城染色體陽性急性淋巴性白血病（Ph+ALL）

6. 2020 年至 2032 年按年齡分類的全球Sprycel市場

• 成年患者
• 兒科患者

7. 全球Sprycel市場（依通路分類），2020 年至 2032 年

• 醫院和診所
• 零售藥局
• 網路藥局
• 專業藥房

8. 2020 年至 2032 年全球Sprycel市場（按地區）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
• 中東
  • GCC
  • 以色列
  • 其他中東地區
• 非洲
  • 北非
  • 中部非洲
  • 南非

第9章 競爭態勢

• Bristol-Myers Squibb（BMS）

第 10 章 章節

• 調查方法
• 關於出版商

Sprycel Market is estimated to be valued at USD 2.34 Bn in 2025 and is expected to reach USD 2.84 Bn by 2032, growing at a compound annual growth rate (CAGR) of 2.8% from 2025 to 2032.

Sprycel is the brand name for dasatinib, a medication used in the treatment of certain types of cancer. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). Dasatinib works by inhibiting the activity of specific tyrosine kinases, which are enzymes involved in the growth and spread of cancer cells. Sprycel is a targeted medication primarily employed in the treatment of certain types of leukemia, specifically acute lymphoblastic leukemia (ALL), characterized by the presence of the Philadelphia chromosome (Ph+ ALL), and chronic myeloid leukemia (CML). Common side effects of Sprycel may include fatigue, headache, nausea, diarrhea, and fluid retention. Some patients may also experience more serious side effects, such as low blood cell counts, liver problems, and bleeding. Close monitoring by healthcare providers is important to manage and address any adverse effects. It is administered to both adults and children aged 12 months and older who are diagnosed with CML. Additionally, it is prescribed for adults and children in the same age group who are afflicted with a specific subtype of acute lymphoblastic leukemia known as Philadelphia chromosome-positive or Ph+ ALL. Leukemia is a malignancy involving immature white blood cells that develop within the bone marrow. In the normal course of events, as these white blood cells mature, they enter the bloodstream to combat infections and maintain the body's immune system.

Market Dynamics:

The increasing prevalence of targeted indications, their efficacy and safety profile, expanded indications, and innovative advancements are major factors expected to drive growth of the global sprycel market during the forecast period. Advancements in cancer research and treatment, including the development of targeted therapies like Sprycel, have expanded the options available to healthcare providers and patients. This has led to increased adoption of Sprycel as part of the treatment regimen.

However, strong competition, patent expiration, regulatory challenges, adverse effects, and pricing and reimbursement are expected to hamper the growth of the global Sprycel market over the forecast period.

Key features of the study:

• This report provides in-depth analysis of the global Sprycel market, and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Sprycel market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bristol-Myers Squibb (BMS)
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Sprycel market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Sprycel market

Detailed Segmentation:

• By Application:
  • Chronic myeloid leukemia (CML)
  • Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
• By Age Group:
  • Adult Patients
  • Pediatric Patients
• By Distribution Channel:
  • Hospitals and Clinics
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Pharmacies
• By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• By Company Profiles:
  • Bristol-Myers Squibb (BMS)

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Global Sprycel, By Application
  • Market Global Sprycel, By Age Group
  • Market Global Sprycel, By Distribution Channel
  • Market Global Sprycel, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing prevalence of targeted indications, efficacy and safety profile, expanded indications
  • Strong competition, patent expiration, regulatory challenges
  • Innovative advancements
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Sprycel Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Sprycel Market, By Application, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Chronic myeloid leukemia (CML)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Sprycel Market, By Age Group, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Adult Patients
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Pediatric Patients
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Sprycel Market, By Distribution Channel, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals and Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Specialty Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Global Sprycel Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Bristol-Myers Squibb (BMS)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us